TY - JOUR
T1 - The clinical efficacy of angiotensin II type1 receptor blockers on inflammatory markers in patients with hypertension
T2 - a multicenter randomized-controlled trial; MUSCAT-3 study
AU - Umebayashi, Ryoko
AU - Uchida, Haruhito A.
AU - Okuyama, Yuka
AU - Kakio, Yuki
AU - Hanayama, Yoshihisa
AU - Shikata, Kenichi
AU - Wada, Jun
N1 - Funding Information:
The authors would like to thank Dr Takanobu Nakajima in Kato and Namiki-dori Hospital, Dr Yasuaki Mino in Ochiai Hospital, Dr Kiichi Komoto, Dr Hiroo Hashimoto, Dr Kazuhiro Ujike in Innnosima General Hospital, Dr Kazuharu Murakami in Murakami Clinic, Dr Hiroshi Hirata in Akebono Clinic, Dr Keita Ishii in Chugoku Central Hospital, Dr Yoshikazu Hayashi in Tujii Hayashi Naika Clinic, Dr Masami Hashimoto in Hashimoto Kidney Clinic, Dr Hideyuki Okamoto in Okamoto Clinic, Dr Kazuhiko Ezawa, Dr Koji Takasugi, Dr Misuzu Fujimori in Kurashiki Kosai Hospital, Dr Kazuyuki Fujino, Dr Takehide Mitogawa, Dr Masanobu Kaihara, Dr Yuichi Kido in Onomichi Municipal Hospital, Dr Masashi Muguruma, Dr Junko Kasahara-Fukuda, Dr Hitomi Kataoka in Okayama Kinen Hospital, Dr Kosuke Yozai in Mitoyo General Hospital, Dr Teruhiko Hattori, Dr Yasuhiko Yoshinaga in Kurashiki Medical Center, Dr Masaru Kinomura in Kurashiki Central Hospital, Dr Masaki Fukushima, Dr Toshie Araki in Shigei Medical Research Hospital, Dr Ryo Nagase in Okayama Rosai Hospital, Dr Taro Sugimoto in Sugimoto Clinic, Dr Hidetoshi Kagawa, Dr Satoshi Hiromasa, Dr Ryutaro Yamanaka in Japanese Red Cross Society Himeji Hospital, Dr Kazushi Harada in Harada Naika Clinic, Dr Yuko Okazaki in Jonan Clinic and Dr Hisanao Norii in Asano Medical Clinic for their kind help to contact with the patients of their institutions.
Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/4/3
Y1 - 2019/4/3
N2 - Purpose: The purpose of present study was to evaluate the clinical efficacy of irbesartan on the anti-inflammatory and anti-oxidative stress effect in patients with hypertension compared to other ARBs. Further, we assessed the effect of the ARBs on kidney function and urinary albumin excretion. Methods: Eighty-five outpatients with hypertension who took an ARB except irbesartan more than 3 months were assigned into two groups, one continued the same ARB and the other switched the ARB to irbesartan for 6 months. Results: Although blood pressures were equally controlled (continue group: 148 ± 2/79 ± 2 mmHg to 131 ± 2/74 ± 2 mmHg; switch group: 152 ± 2/81 ± 2 mmHg to 132 ± 2/74 ± 2 mmHg; p < 0.001 each), the inflammatory markers (hsCRP, PTX3, MCP-1) and oxidative stress marker (MDA-LDL) did not change after 6 months in both groups. Urinary albumin excretion was significantly reduced only in the switch group without renal function deterioration (switch group 292.4 ± 857.9 mg/gCr to 250.6 ± 906.5 mg/gCr, p = 0.012). Conclusion: These results provide knowledge of the characteristics of irbesartan, suggesting appropriate choice of ARBs in the treatment for hypertension should be considered.
AB - Purpose: The purpose of present study was to evaluate the clinical efficacy of irbesartan on the anti-inflammatory and anti-oxidative stress effect in patients with hypertension compared to other ARBs. Further, we assessed the effect of the ARBs on kidney function and urinary albumin excretion. Methods: Eighty-five outpatients with hypertension who took an ARB except irbesartan more than 3 months were assigned into two groups, one continued the same ARB and the other switched the ARB to irbesartan for 6 months. Results: Although blood pressures were equally controlled (continue group: 148 ± 2/79 ± 2 mmHg to 131 ± 2/74 ± 2 mmHg; switch group: 152 ± 2/81 ± 2 mmHg to 132 ± 2/74 ± 2 mmHg; p < 0.001 each), the inflammatory markers (hsCRP, PTX3, MCP-1) and oxidative stress marker (MDA-LDL) did not change after 6 months in both groups. Urinary albumin excretion was significantly reduced only in the switch group without renal function deterioration (switch group 292.4 ± 857.9 mg/gCr to 250.6 ± 906.5 mg/gCr, p = 0.012). Conclusion: These results provide knowledge of the characteristics of irbesartan, suggesting appropriate choice of ARBs in the treatment for hypertension should be considered.
KW - Angiotensin II receptor blocker
KW - albuminuria
KW - hypertension
KW - inflammation
KW - oxidative stress
UR - http://www.scopus.com/inward/record.url?scp=85057585448&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057585448&partnerID=8YFLogxK
U2 - 10.1080/1354750X.2018.1548033
DO - 10.1080/1354750X.2018.1548033
M3 - Article
C2 - 30444137
AN - SCOPUS:85057585448
VL - 24
SP - 255
EP - 261
JO - Biomarkers
JF - Biomarkers
SN - 1354-750X
IS - 3
ER -